StockData
Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc. (DWTX) stock

DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.08+0.00 (0.00%)

Close on Nov 18, 2026Market cap $36.71MP/E –Yield –

Dogwood Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Dogwood Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.11M. For fiscal 2025 it was -$15.62M. The highest annual figure on record is -$3.90M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.62M–
FY2024Dec 31, 2024-$8.79M–
FY2023Dec 31, 2023-$4.87M–
FY2022Dec 31, 2022-$11.47M–
FY2021Dec 31, 2021-$15.69M–
FY2020Dec 31, 2020-$3.90M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.61M–
Q1 FY2026Mar 31, 2026-$4.59M–
Q4 FY2025Dec 31, 2025-$3.64M–
Q3 FY2025Sep 30, 2025-$3.27M–
Q2 FY2025Jun 30, 2025-$4.03M–
Q1 FY2025Mar 31, 2025-$4.68M–
Q4 FY2024Dec 31, 2024-$6.13M–
Q3 FY2024Sep 30, 2024-$910.14K–
Q2 FY2024Jun 30, 2024-$811.75K–
Q1 FY2024Mar 31, 2024-$937.41K–
Q4 FY2023Dec 31, 2023-$1.47M–
Q3 FY2023Sep 30, 2023-$960.45K–
Q2 FY2023Jun 30, 2023-$742.41K–
Q1 FY2023Mar 31, 2023-$1.70M–
Q4 FY2022Dec 31, 2022-$2.67M–
Q3 FY2022Sep 30, 2022-$2.48M–
Q2 FY2022Jun 30, 2022-$3.66M–
Q1 FY2022Mar 31, 2022-$2.66M–
Q4 FY2021Dec 31, 2021-$5.18M–
Q3 FY2021Sep 30, 2021-$2.65M–
Q2 FY2021Jun 30, 2021-$2.75M–
Q1 FY2021Mar 31, 2021-$5.11M–
Q4 FY2020Dec 31, 2020-$2.29M–
Q3 FY2020Sep 30, 2020-$558.89K–
Q2 FY2020Jun 30, 2020-$772.57K–
Q1 FY2020Mar 31, 2020-$277.38K–

More Dogwood Therapeutics figures

See a number that looks wrong?